SCHEMBL2880301

SCHEMBL2880301

CON(C)C(=O)c1cnc(C)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.44
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPK1 P28482 2/20 0.35
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
NNMT P40261 1/20 0.34
CLK1 P49759 1/20 0.34
DYRK1A Q13627 1/20 0.34
DYRK1B Q9Y463 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
ICAM1 P05362 1/20 0.34
SELE P16581 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1436840 0.82 HDAC1 (0.50) MLYCDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL12975492 0.81 KMT2A (0.42) KDM4EALDH1A1ALOX15HSD17B10MEN1
SCHEMBL19107778 0.80 MLYCD (0.39) MLYCDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL17823828 0.78 MLYCD (0.50) MLYCDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL2253612 0.78 MLYCD (0.46) MLYCDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL3542739 0.78 MLYCD (0.40) MLYCDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL2507311 0.78 HCAR2 (0.46) MLYCDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL25294618 0.77 MLYCD (0.39) MLYCDKDM4EALDH1A1ALOX15HSD17B10
SCHEMBL2571770 0.77 MLYCD (0.49) MLYCDKDM4EMAPK1PIK3CAMTOR
SCHEMBL15057209 0.77 NNMT (0.53) MLYCDKDM4EMAPK1PIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
CN-117715909-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-03-15 CN disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed
US-10167300-B2 Metalloenzyme inhibitor compounds as fungicides DOW AGROSCIENCES LLC (US) 2019-01-01 US disclosed
US-20180298038-A1 METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES DOW AGROSCIENCES LLC (US) 2018-10-18 US disclosed
US-9944664-B2 Metalloenzyme inhibitor compounds as fungicides DOW AGROSCIENCES LLC (US) 2018-04-17 US disclosed
US-20150291632-A1 METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES DOW AGROSCIENCES LLC 2015-10-15 US disclosed
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MSD K.K. (JP) 2010-12-23 US disclosed
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MSD K.K. (JP) 2010-12-23 US disclosed
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US disclosed
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US disclosed
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US disclosed
EP-2072519-A1 DIARYL KETIMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-24 EP disclosed
EP-2072519-A1 DIARYL KETIMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 MLYCD 213/4885KDM4E 3515/4885ALDH1A1 2000/4885
US-10167300-B2 Metalloenzyme inhibitor compounds as fungicides GPX1, POR, MGAM MLYCD 226/4885KDM4E 2055/4885ALDH1A1 180/4885
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MC1R, MCHR1, MCHR2 MLYCD 2120/4885KDM4E 2707/4885ALDH1A1 1234/4885
US-20150291632-A1 METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES GPX1, POR, MGAM MLYCD 226/4885KDM4E 2055/4885ALDH1A1 180/4885
US-20090247560-A1 Diaryl ketimine derivative NR0B2, NR2C2, NR3C2 MLYCD 1554/4885KDM4E 1981/4885ALDH1A1 872/4885
US-20180298038-A1 METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES GPX1, POR, MGAM MLYCD 226/4885KDM4E 2055/4885ALDH1A1 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.